Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YXL
|
|||
| Former ID |
DIB016133
|
|||
| Drug Name |
PEGylated IFN beta 1-a
|
|||
| Synonyms |
BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Approved | [1], [2] | |
| Company |
Biogen idec
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02234869) Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.